P/B
1,3
Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
$101.8B
Market Cap • 9/11/2026
1994
(32 years)
Founded
2002
(24 years ago)
IPO
NASDAQ
Listing Exchange
France
Country
Valuation
P/S
1,8
P/EBITDA
7
P/OCF
5,7
P/FCF
7,3
P/E
22,3
BVPS
32,7
EPS
1,9
Market Cap
Market Cap
101,8B
EV
121,9B
EV/Revenue
2,1
EV/EBITDA
8,4
EV/EBIT
18,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
2,1%
Total Yield
2,1%
Dividend Yield 5Y
1%
Payout
0%
Profitability
Gross Margin
72,7%
EBITDA Margin
25,6%
EBIT Margin
11,8%
Net Margin
8,7%
D&A/EBITDA
16,7%
R&D/Revenue
16,6%
Capex/Revenue
7%
Capex/D&A
50,4%
Capex/OCF
22,1%
SBC/OCF
2,1%
% PPE
9,3%
% Goodwill
32,5%
ROE
6,1%
ROIC
4,4%
Growth
CAGR Revenue 5Y
4%
CAGR Op. Income 5Y
-5,8%
CAGR Net Income 5Y
-6,4%
CAGR EPS 5Y
-6,9%
CAGR OCF 5Y
17,5%
Leverage
N.D./EBITDA
1,4
Debt/Equity
0%
Current Ratio
1
Quick Ratio
0,5
Interest Coverage
867,3%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!